Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus

Patients with type 2 diabetes mellitus (T2DM) have a very high risk of cardiovascular related events, and reducing complications is an important evaluation criterion of efficacy and safety of hypoglycemic drugs. Previous studies have shown that the dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP4i),...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, De-kang, Xiao, Qian, Li, Fa-qi, Tang, Yu-zhi, Jia, Chao-li, Tang, Xue-wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629947/
https://www.ncbi.nlm.nih.gov/pubmed/31262972
http://dx.doi.org/10.1042/BSR20190980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629947/
https://www.ncbi.nlm.nih.gov/pubmed/31262972
http://dx.doi.org/10.1042/BSR20190980

Ejemplares similares